Innate Pharma SA IPHA 深 沪
已收盘 08-14 16:00:00 美东时间
2.18
-0.355
-14.00%
华盛通- 最 高2.24
- 今 开2.18
- 成交量 10.58万股
- 最 低 2.1216
- 昨 收 2.535
- 总市值 2.05亿
- 52周最高 2.71
- 市盈率 静 --
- 换手率 0.11%
- 52周最低 1.17
- 委 比 -96.58%
- 总股本 9390.33万
- 历史最高 11.95
- 量 比 0.07
- 振 幅 4.67%
- 历史最低 1.17
- 每 手 1
- 风险率 0.25%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 业绩大超预期！ CoreWeave、超微电脑、Lumentum绩后获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从49美元升至56美元；韦德布什：维持Zura Bio"跑赢大市"评级，目标价从15美元升至22美元
08-13 11:44
美股牛股 | BWNM飙升55%，获私募巨头溢价近6成收购；获华尔街投行齐声看多，STDN劲升35%；医药股ABCL大涨34%
BWNM飙升55%，获私募巨头溢价近6成收购；STDN劲升35%，机构称其在三结构各向同性核燃料市场中；医药股ABCL升超34%，潮热治疗药物中期试验效果积极>>
08-11 15:48
美股大行评级 | Take-Two、Csquare、Standard获多家大行首予买入评级！潜在涨幅215.32%！HC Wainwright.升Innate Pharma(IPHA)目标价至7美元
今日重点评级关注：HC Wainwright & Co.：维持Innate Pharma"买入"评级，目标价从5美元升至7美元；HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从20美元升至25美元
08-11 11:45
Innate Pharma Jumps as Sobi Deal Boosts Secured Financing for Advancing Rare Skin Cancer Therapy
Swedish Orphan Biovitrum AB (Sobi) and Innate Pharma SA (NASDAQ:IPHA) on Monday forged a strategic alliance to launch a critical Phase 3 clinical trial targeting a rare form of skin cancer. The collaboration primarily focuses on enabling the TELLOMAK-3 study, a crucial milestone intended to fast-tra...
08-10 22:03
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Alpha Compute (NASDAQ:ALP) shares increased by 71.3% to $0.46 during T...
05-14 20:05
Innate Pharma Advances Lacutamab Phase 3 Trial And IPH4502 ADC Amid €25.4M Cash Runway Through Q3 2026
Lacutamab TELLOMAK-3 confirmatory Phase 3 trial in cutaneous T-cell lymphoma (CTCL) remains planned for initiation in H2 2026, subject to non-dilutive financing options currently under negotiation, including pharma
05-13 13:31
Innate Pharma To Present Phase 2 MATISSE Prospectus Data On IPH5201 Combo In Resectable Lung Cancer At AACR 2026
Encouraging early results catalyze continued investigation in the MATISSE Phase 2 study evaluating IPH5201, a first-in-class anti-CD39 monoclonal antibody, in combination with durvalumab and chemotherapy in resectable
04-18 03:01
美股大行评级 | 高盛首予PayPay“买入”评级；神经分泌生物科学获花旗等多家机构上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Enlivex"买入"评级，目标价从13美元升至20美元；韦德布什：维持FuboTV"跑赢大市"评级，目标价从3.5美元升至24美元
04-08 18:35
HC Wainwright & Co. Reiterates Buy on Innate Pharma, Maintains $5 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Innate Pharma (NASDAQ:IPHA) with a Buy and maintains $5 price target.
04-08 01:45
